Saeed Mohammad1, Carlo Di Lorenzo, Nader N Youssef, Adrian Miranda, Samuel Nurko, Paul Hyman, Miguel Saps. 1. *Division of Pediatric Gastroenterology, Hepatology and Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Feinberg School of Medicine, Chicago, IL †Division of Gastroenterology, Nationwide Children's Hospital, Columbus, OH ‡Digestive Healthcare Center, Hillsborough, NJ §Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Medical College of Wisconsin, Milwaukee, WI ||Center for Motility and Functional Gastrointestinal Disorders, Children's Hospital Boston, Boston, MA ¶Division of Pediatric Gastroenterology, Children's Hospital of New Orleans, New Orleans, LA.
Abstract
OBJECTIVES:Irritable bowel syndrome is a multisymptom construct, with abdominal pain (AP) acting as the driving symptom of patient-reported severity. The Food and Drug Administration considers a >30% decrease in AP as satisfactory improvement, but this has not been validated in children. We investigated the correspondence of 2 measures for AP assessment, ≥30% improvement in AP and global assessment of improvement. METHODS: Secondary analysis of data from 72 children who completed a randomized clinical trial for abdominal pain-associated functional gastrointestinal disorders. Children completed daily assessment of AP intensity, functional disability inventory (FDI), question regarding pain's interference with activities, and 2 global assessment questions. We measured the extent to which ≥30% improvement of AP and global assessment questions correlated with each other and with disability. RESULTS: The global questions correlated with each other (r=0.74; P<0.0001) and with a ≥30% improvement in AP (P<0.01). Global outcomes were satisfaction with treatment was inversely related to the child's report of interference with activities (P<0.01) and symptom relief was positively associated with ≥30% improvement in FDI scores (P<0.009). A 30% change in FDI scores was associated with global questions of symptom relief (P=0.009) but not with satisfaction with treatment (P=0.07). The association of AP improvement with interference with activities (P=0.14) or change in FDI scores (P=0.27) did not reach significance. CONCLUSIONS: Currently used global assessments are significantly associated with decreased pain intensity, decreased interference with daily activities, and a ≥30% change in FDI scores, whereas recommended 30% improvement in pain intensity is not as comprehensive.
RCT Entities:
OBJECTIVES:Irritable bowel syndrome is a multisymptom construct, with abdominal pain (AP) acting as the driving symptom of patient-reported severity. The Food and Drug Administration considers a >30% decrease in AP as satisfactory improvement, but this has not been validated in children. We investigated the correspondence of 2 measures for AP assessment, ≥30% improvement in AP and global assessment of improvement. METHODS: Secondary analysis of data from 72 children who completed a randomized clinical trial for abdominal pain-associated functional gastrointestinal disorders. Children completed daily assessment of AP intensity, functional disability inventory (FDI), question regarding pain's interference with activities, and 2 global assessment questions. We measured the extent to which ≥30% improvement of AP and global assessment questions correlated with each other and with disability. RESULTS: The global questions correlated with each other (r=0.74; P<0.0001) and with a ≥30% improvement in AP (P<0.01). Global outcomes were satisfaction with treatment was inversely related to the child's report of interference with activities (P<0.01) and symptom relief was positively associated with ≥30% improvement in FDI scores (P<0.009). A 30% change in FDI scores was associated with global questions of symptom relief (P=0.009) but not with satisfaction with treatment (P=0.07). The association of AP improvement with interference with activities (P=0.14) or change in FDI scores (P=0.27) did not reach significance. CONCLUSIONS: Currently used global assessments are significantly associated with decreased pain intensity, decreased interference with daily activities, and a ≥30% change in FDI scores, whereas recommended 30% improvement in pain intensity is not as comprehensive.
Authors: Patrick J McGrath; Gary A Walco; Dennis C Turk; Robert H Dworkin; Mark T Brown; Karina Davidson; Christopher Eccleston; G Allen Finley; Kenneth Goldschneider; Lynne Haverkos; Sharon H Hertz; Gustaf Ljungman; Tonya Palermo; Bob A Rappaport; Thomas Rhodes; Neil Schechter; Jane Scott; Navil Sethna; Ola K Svensson; Jennifer Stinson; Carl L von Baeyer; Lynn Walker; Steven Weisman; Richard E White; Anne Zajicek; Lonnie Zeltzer Journal: J Pain Date: 2008-06-17 Impact factor: 5.820
Authors: Arine M Vlieger; Carla Menko-Frankenhuis; Simone C S Wolfkamp; Ellen Tromp; Marc A Benninga Journal: Gastroenterology Date: 2007-09-02 Impact factor: 22.682
Authors: James W Varni; Robert J Shulman; Mariella M Self; Samuel Nurko; Miguel Saps; Shehzad A Saeed; Ashish S Patel; Chelsea Vaughan Dark; Cristiane B Bendo; John F Pohl Journal: Qual Life Res Date: 2016-10-14 Impact factor: 4.147
Authors: James W Varni; Cristiane B Bendo; Robert J Shulman; Mariella M Self; Samuel Nurko; James P Franciosi; Miguel Saps; Shehzad Saeed; George M Zacur; Chelsea Vaughan Dark; John F Pohl Journal: J Pediatr Psychol Date: 2015-02-13
Authors: John M Hollier; Danita I Czyzewski; Mariella M Self; Erica M Weidler; E O'Brian Smith; Robert J Shulman Journal: J Pediatr Gastroenterol Nutr Date: 2017-03 Impact factor: 2.839
Authors: John M Hollier; Danita I Czyzewski; Mariella M Self; Yan Liu; Erica M Weidler; Miranda A L van Tilburg; James W Varni; Robert J Shulman Journal: J Clin Gastroenterol Date: 2021 May-Jun 01 Impact factor: 3.174
Authors: Wendy A Henderson; Bridgett Rahim-Williams; Kevin H Kim; LeeAnne B Sherwin; Sarah K Abey; Angela C Martino; Nicolaas H Fourie; Margaret M Heitkemper; Anthony P Zuccolotto Journal: Gastroenterol Nurs Date: 2017 Sep/Oct Impact factor: 0.978